Physician profile

Michael D Smith

Obstetrics · Raleigh, NC

NPI 1992707533

$314.11

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $73.10 2019-2021
Duchesnay USA Incorporated $36.32 2019
Daiichi Sankyo INC. $34.38 2019
Exeltis, USA INC. $33.73 2022
Abbvie INC. $30.86 2019-2022
Amag Pharmaceuticals, INC. $25.06 2019-2020
Hologic Sales and Service, LLC $22.28 2022
Organon LLC $22.20 2023 Nexplanon
Mylan Pharmaceuticals INC. $13.80 2019
Therapeuticsmd, INC. $11.37 2019
Lupin INC. $11.01 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Smith

$314.11

in general payments reported 2019-2025

Years
2019-2023
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/618991/michael-d-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.